Merck Applies To Extend Use Of Erbitux For 1st-Line Head And Neck Cancer In Europe
Added: 21 июня 2008
Last relative articles:
- State-of-the-Art Lecture: What Are The Most Important Ongoing Clinical Trials In Urologic Oncology Worldwide?
- 5 Top Young Clinical Investigators Receive Damon Runyon Cancer Research Foundation Awards
- State-of-the-Art Lecture: Aptomers Of Nanotechnology - Reported From The Annual Meeting Of The American Urological Association
- AAD, MLB And MLB Players Association Play Sun Smart To Strike Out Skin Cancer
- Oncolin Therapeutics Announces Its Cancer Technology Will Be Presented At The 20th EORTC-NCI-AACR Symposium
- CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab Erbitux
- Melanoma Is On The Rise In Women
- Indiana University Simon Cancer Center Priority: Reduce Cancer Incidences, Mortality Among State's Diverse Populations
- Obesity Surgery May Reduce Cancer Risk
- Japan Approves CyberKnife System For Extracranial Use - Non-Invasive Treatment Alternative For Tumors Anywhere In The Body
Comments: [0] / Post comment:
08 Jan 2009 02:56:00
Erbitux First Line in MCRC? Let's not get carried away. - Gerson Lehrman Group
Erbitux First Line in MCRC? Let's not get carried away. Gerson Lehrman Group, New York - ... not move into first line unless improved efficacy is shown in a direct comparison. SO before anointing Erbitux the drug of choice, let's await the data.
08 Jan 2009 01:26:23
Wyeth In Talks To Buy Crucell - Forbes
Wyeth In Talks To Buy Crucell Forbes, NY - ... for access to its cancer treatment Erbitux . During the summer, Swiss drugmaker Roche (other-otc: RHHBY - news - people ) scooped up privately held Mirus ...
05 Jan 2009 15:01:44
Merck Serono: Study Published In JCO Shows Erbitux Enhances ... - Medical News Today (press release)
Merck Serono: Study Published In JCO Shows Erbitux Enhances ... Medical News Today (press release), UK - A study published today in the Journal of Clinical Oncology demonstrates that the addition of Erbitux (cetuximab) to standard oxaliplatin-based ...
03 Jan 2009 01:10:32
Gastrointestinal Cancers Symposium Program Announced - EndoNurse
Gastrointestinal Cancers Symposium Program Announced EndoNurse, AZ - ... with KRAS gene testing in patients with metastatic colorectal cancer, and using gene status to guide use of the targeted therapy cetuximab ( Erbitux ). ...
30 Dec 2008 16:15:27
Advocates push 'personalized medicine' - United Press International
Advocates push 'personalized medicine' United Press International - Colon cancer drugs Erbitux and Vectibix, for instance, do not work for the 40 percent of patients whose tumors have a particular genetic mutation, ...
23 Dec 2008 19:17:17
Bittersweet Gene - Curetoday.com (press release)
Bittersweet Gene Curetoday.com (press release), TX - The drug Goldberg had in mind was Erbitux (cetuximab), which belongs to a growing family of targeted therapies that are changing the way doctors approach ... KRAS as a Target Chronicling KRAS
23 Dec 2008 17:03:12
Cancer Medicine Advances on Many Fronts - Washington Post
Modern Medicine Cancer Medicine Advances on Many Fronts Washington Post, United States - Cetuximab ( Erbitux ), a monoclonal antibody, when added to chemotherapy, increased overall survival by as much as 21 percent in patients with non-small cell ... ASCO reports 12 major advances in cancer care in 2008 Report Lauds 2008's Important Cancer Discoveries American Society ...
17 Dec 2008 00:29:32
Lilly, Amgen Want to Match Their Cancer Drugs to Patient Genes - Bloomberg
Lilly, Amgen Want to Match Their Cancer Drugs to Patient Genes Bloomberg - s Erbitux and Amgens Vectibix ineffective in colon cancer patients. Recent findings on the gene may lead to new rules for prescribing treatments based on a ... Amgen, ImClone Seeking FDA OK To Relabel Colon Cancer Drugs FDA Panel Mulls Criteria for Accepting Retrospective Data for Rx ... FDA Cancer Drug Meeting Could Provide Insight into Agency's Rx Dx ... -
Source: http://bloomberg.com/apps/news
16 Dec 2008 23:59:57
Bristol-Myers Sets More Job Cuts - Wall Street Journal
Wall Street Journal Blogs Bristol-Myers Sets More Job Cuts Wall Street Journal - Bristol-Myers had a strong third quarter, thanks to sales of the cancer drug Erbitux , which it co-markets with ImClone Systems Inc. But, like others in the ... Bristol-Myers will layoff yet another 10% Bristol-Myers to cut additional 10% of workforce - Update
12 Dec 2008 23:08:12
Cancer Med Labels May Reflect Genetic Issues - Pharmalot
Pharmalot Cancer Med Labels May Reflect Genetic Issues Pharmalot, NJ - The meeting is being held to discuss whether to recommend that doctors screen patients for the so-called KRAS gene mutation before prescribing Erbitux , ... FDA questions Lilly, Amgen cancer drug trials FDA to Consider Lower Standards for Amgen and ImClone in Cancer ... US FDA questions Lilly, Amgen cancer drug trials